Researchers eye SYK inhibitors for retinoblastoma
This article was originally published in Scrip
Experimental drugs that block the SYK could prove effective treatments for the aggressive childhood cancer retinoblastoma if it proves possible to reformulate them for ocular use, researchers from St Jude's Children's Research Hospital have found.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.